Movicol (Macrogol)

Quick links to important sections

Movicol (Macrogol)

Method of action: Laxative

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Movicol (Macrogol)

Movicol is a well-established, over-the-counter combination preparation used to facilitate the comfortable and regular evacuation of the bowels. It is officially classified as an osmotic laxative, a type of medicine that uses physical principles—drawing water into the colon—to soften and increase stool volume.

Property Description
Active ingredient Macrogol 3350 (Polyethylene Glycol)
Form Powder for oral solution (sachet)
Pharmacological class Osmotic Laxative
Common purpose Promotes comfortable and regular bowel movement
Origin Synthetic polymer, combined with electrolytes

Defining Movicol: Identity and Pharmacological Classification

Movicol belongs to the osmotic laxative pharmacological class, defined by its mechanism of drawing and retaining water in the intestinal lumen. The primary active component is the high-molecular-weight compound Macrogol 3350 (or Polyethylene Glycol, PEG), which drives the laxative effect. Macrogol is considered biologically inert and non-absorbable, meaning its action is localized entirely within the gastrointestinal tract, minimizing systemic effects. This agent is clinically recognized for its use in treating prolonged, difficult bowel movements, often when dietary changes alone prove insufficient.


Composition and Differentiation: Electrolyte Balance

The core active ingredient, Macrogol 3350, is a synthetic polymer that is neither digested nor fermented by the body. As a combination product, a key feature is its deliberate formulation to include a balanced mix of essential electrolytes—specifically Sodium Chloride, Potassium Chloride, and Sodium Bicarbonate. These electrolytes serve a critical function: they are added to ensure that the patient’s natural fluid and salt balance is maintained during the process of water retention in the colon, supporting safe application for management without significantly affecting the body's essential ion concentrations.


General Purpose of the Osmotic Action

The general purpose of the medicine is to achieve significant stool softening and increase the stool volume to support natural bowel function. By utilizing its powerful water-binding property, Macrogol ensures the faeces retain high moisture content, which facilitates smoother passage. Use of polyethylene glycol 3350 plus electrolytes supports sustained improvement in bowel function. This mechanism assists in establishing a more regular and physically comfortable pattern of evacuation, reducing straining and discomfort.

Regulatory References

  1. Polyethylene Glycol (Macrogol) definition
  2. Polyethylene Glycol 3350 plus electrolytes efficacy

What side effects are possible with Movicol (Macrogol)?

Possible side effects and safety information

Official regulatory documentation structures the safety profile of Macrogol 3350 with electrolytes primarily around gastrointestinal effects and the potential for systemic fluid shifts. Reactions involving the gastrointestinal tract occur most commonly overall, with severity sometimes increasing during the treatment phase for fecal impaction.

The majority of adverse reactions are classified by frequency as follows:

  • Very Common: Abdominal pain, borborygmi (stomach rumbling).
  • Common: Diarrhoea, vomiting, nausea, anorectal discomfort.
  • Uncommon: Abdominal distension, flatulence.

Serious Reactions and Safety Constraints

Safety labeling specifies the potential for serious adverse reactions related to fluid and electrolyte imbalance. These may be indicated by symptoms such as peripheral oedema, shortness of breath, increasing fatigue, dehydration, or, in severe cases, be associated with cardiac failure. Immune system disorders are also documented, including allergic reactions like urticaria, rash, and the rare occurrence of anaphylaxis.

Use of the product is Contraindicated in individuals with pre-existing intestinal perforation or obstruction, ileus, severe inflammatory conditions of the intestinal tract (e.g., toxic megacolon), or known hypersensitivity to the components. Furthermore, the label notes that the absorption of other concurrently administered medicines, such as anti-epileptics, may be transiently reduced. Official regulatory notes indicate that the use during pregnancy is generally considered acceptable due to negligible systemic exposure, but should be restricted to when deemed essential.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Macrogol 3350 with electrolytes is documented in regulatory labeling as resulting primarily in clinical signs of excessive volume loss. The expected principal manifestation of overdosage is severe diarrhoea, often accompanied by severe abdominal pain and abdominal distension. This excessive fluid loss can lead to systemic complications, including dehydration and critical electrolyte disorders such as hyponatraemia and hypokalaemia.

Required Emergency Action

Regulatory authorities mandate that you seek immediate medical attention for all suspected or severe overdose scenarios. You are also instructed to immediately contact a Poison Control Center and stop administration of the medicine. These actions are necessary because the resultant severe electrolyte imbalances carry a risk of life-threatening events, including seizures and cardiac arrhythmias, particularly in vulnerable populations.

Official Management and Monitoring

Management described in official documents is purely symptomatic and supportive. As no specific antidote is known, care focuses on the mandatory correction of electrolyte disturbances. Severe metabolic derangement may require intravenous rehydration to stabilize the patient. Overdose risk is documented as higher for patients with impaired hepatic or renal function and the elderly, due to their increased vulnerability to water-electrolyte balance disorders.

Therapeutic Uses of Movicol (Macrogol)

What Movicol (Macrogol) Treats: Main Uses and Benefits

Macrogol (Polyethylene Glycol 3350) is generally applied in situations involving certain distressing symptoms that interfere with daily functioning, associated with bowel irregularity. It is considered relevant when supportive symptom management is appropriate across its key therapeutic contexts, including chronic and functional constipation and the management of fecal impaction.

The medication is commonly used across conditions presenting with acute or recurrent episodes, and may assist with addressing specific symptom clusters. It is relevant for managing symptoms that interfere with daily comfort, such as straining, hard stools, and infrequency. Applied during phases when symptoms become more noticeable, it contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

It is also relevant for easing symptoms that develop secondary to other health issues, like reduced mobility or as an effect of certain medications (e.g., opioids). Macrogol may be part of symptomatic management for conditions where symptoms may intensify temporarily, contributing to supportive relief when short-term symptomatic assistance is needed.


Quick Fact: Relief for Heightened Symptoms Macrogol is commonly used to help with conditions where symptoms may intensify temporarily, contributing to supportive relief when short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Movicol (Macrogol)

Official regulatory information strictly defines the populations who can and cannot use Macrogol 3350. The most critical restrictions are the absolute contraindications related to the digestive system. Movicol must not be used by patients with a perforated gut wall, intestinal obstruction (ileus), or severe inflammatory bowel diseases, including Toxic Megacolon, Ulcerative Colitis, or Crohn's Disease. It is also contraindicated for those with a known hypersensitivity to Macrogol or any excipients.

Age-Related Eligibility

The standard adult formulation is generally not recommended for children below 12 years of age in European labeling, though pediatric-specific formulations are available. US OTC labeling restricts use to adults and children 17 years of age and older, advising younger patients to consult a doctor. Use is permitted for adults and adolescents 12 years and over.

Special Populations and Restrictions

Use is permitted for pregnant and breastfeeding women due to the negligible systemic absorption of the active ingredient. Patients with renal insufficiency typically do not require a dose adjustment. However, patients with Impaired Cardiovascular Function treating fecal impaction must adhere to a strict restriction of no more than two sachets in any one hour.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Macrogol with electrolytes is strictly defined by its physical mode of action, as the compound is virtually non-absorbed. Regulatory documents confirm that Macrogol is not involved in systemic metabolic interactions, such as those mediated by the CYP450 enzyme system, thus no such classic pharmacokinetic interactions are documented.

The officially recognized interactions stem from the product's primary pharmacodynamic effect, which is to significantly increase the transit rate of contents through the gastrointestinal tract. This mechanism introduces two main interaction-related constraints: a timing rule and a physical incompatibility.

Interactions and Regulatory Constraints

Interaction Type Official Regulatory Description Resulting Constraint
Reduced Absorption of Oral Medicines The increased gastrointestinal transit rate may cause a transient decrease in the plasma exposure of co-administered oral medicinal products, potentially lowering their efficacy. Mandatory separation of administration time is required to mitigate this risk of transiently reduced absorption.
Timing-Based Separation Rule Other oral medicines must not be taken orally for one hour before, during, and one hour after the administration of Macrogol with electrolytes. This mandates a specific two-hour window for all other oral solid or liquid dosage forms.
Physical Incompatibility (Food/Thickeners) Macrogol is documented to counteract the thickening effect of starch-based food thickeners, causing the thickened liquid to become watery. This physical constraint is an elevated consideration for individuals with swallowing difficulties, as the liquefaction may compromise safe fluid consistency.

The reduction in efficacy of certain co-administered medicines, notably specific anti-epileptics, has been described in isolated case reports consistent with this mechanism of reduced absorption.

Mechanism of Action

Osmotic Water Retention and Volumetric Increase

The mechanism is driven by the physical chemistry of Macrogol 3350, a biologically inert polymer that operates peripherally without targeting receptors or enzymes. Instead, it binds free water molecules in the colonic lumen through hydrogen bonding, thereby generating an osmotic gradient. This action increases the volume and water content of the stool mass, which is the necessary physical step for initiating the physiological cascade.


Indirect Activation of Colonic Motility

The physical consequence of the increased stool volume is distension of the bowel wall. This mechanical stretching activates the intrinsic intestinal neuromuscular pathways in the colon, triggering a reflex response. This process modulates propulsive colonic motility by increasing the coordinated movement of the bowel, leading to the transportation and eventual expulsion of the softened mass.


Support of Systemic Isotonicity

As a combination product, the formulation includes balanced electrolytes (sodium, potassium). This component is mechanistic, as it facilitates the resultant fluid remaining isotonic with the body's plasma. This mechanism of systemic homeostasis supports the localization of the osmotic shift to the colon, mitigating a net loss of essential fluid or ions from the systemic circulation.

Dosage and Administration Information

The Movicol formulation, which contains Macrogol 3350 with electrolytes, is designated for oral administration as a solution. Official instructions mandate that the contents of each sachet must be dissolved in 125 ml of water before ingestion, with the exception of the high-dose regimen where up to eight sachets may be combined into 1 litre of water. The product may be administered at any time of the day, independent of meal consumption.


Official Dosing and Duration Regimens

The usage protocol is defined by the condition being addressed, establishing distinct dosage ranges and treatment courses.

Indication Standard Adult Dosing Typical Duration Constraint
Chronic Constipation 1 to 3 sachets daily in divided doses (starting at one) Does not normally exceed two weeks
Faecal Impaction 8 sachets daily Does not normally exceed three days

The dose for chronic constipation is often adjusted downward for long-term maintenance, while the regimen for faecal impaction requires the full daily amount to be consumed within a 6-hour period. A specific procedural constraint in official labeling addresses the high-dose impaction treatment for patients with impaired cardiovascular function, restricting intake to no more than two sachets within any one hour. Furthermore, official usage guidelines recommend separating the administration of other oral medicines by one hour before and after taking the solution, as Macrogol may transiently reduce the absorption of concurrently taken oral products. No official dose adjustments are specified for use in older adults or in cases of renal impairment.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Macrogol (Polyethylene Glycol or PEG) is an osmotic laxative widely investigated and used for the management of chronic constipation and faecal impaction in both adult and paediatric populations. Clinical evidence for formulations containing macrogol 3350 with electrolytes (PEG+E) is extensive, often comparing it to placebo or other common laxatives like lactulose.


Efficacy and Comparative Studies

Studies, including systematic reviews and randomized controlled trials (RCTs), consistently report that PEG-based treatments are associated with an increased frequency of weekly bowel movements compared to placebo in patients with chronic functional constipation.

Population Studied Key Comparative Findings
Adults PEG+E was found to be more effective than placebo and, in some trials, more effective than lactulose in improving stool frequency and consistency.
Children Cochrane reviews indicate that PEG-based treatments are often more effective than or equivalent to lactulose for managing chronic constipation in the paediatric group.

Safety and Long-Term Use

Macrogol is minimally absorbed in the gut, which is associated with a low risk of systemic side effects. Research suggests that it is well-tolerated across various age groups, including elderly subjects and children, and is suitable for use over extended periods. Common side effects reported in clinical trials were generally mild and digestive in nature, such as abdominal bloating, flatulence, or mild diarrhoea.

Ongoing clinical trials continue to explore the use of macrogol in special populations, such as critically ill children, and its effectiveness in combination with digital tools to support treatment adherence.

Frequently Asked Questions (FAQ)

Common questions about Movicol (Macrogol) (FAQ)


Q: What is the difference between Movicol and generic Macrogol?

A: Movicol is a specific brand formulation that contains the active ingredient Macrogol 3350 combined with a balanced mix of electrolytes (salts like sodium and potassium). Official product information notes that the addition of these electrolytes helps to support the body's natural fluid balance during the osmotic process. Generic macrogol formulations may or may not contain these additional components.


Q: How quickly does Movicol usually start to work?

A: Official patient information often indicates that the effect is not immediate, as the medicine works by drawing water into the stool over time. Relief is commonly experienced within 24 to 48 hours after beginning treatment, though the individual time to effect can vary.


Q: Is it normal to feel bloated when first taking Movicol?

A: Yes, regulatory documents list abdominal bloating and flatulence (gas) as common side effects. These effects are related to the medicine's mechanism of action, which involves increasing the volume of fluid and gas in the colon. These symptoms often lessen as the body adjusts to the treatment or if a person's dose is reduced.


Q: Do you need a prescription to buy Movicol?

A: The medicine is widely available in many regions as an over-the-counter (OTC) product. This means a prescription is generally not required to purchase it. However, official information notes that specific high-dose regimens or certain paediatric formulations may only be available through a prescription.


Q: Are there different flavors of Movicol available?

A: Official information confirms that Movicol is available in several versions. These include flavour-free (Plain) and various flavoured formulations, such as Chocolate or Lemon-Lime. The choice of flavour does not change the core effectiveness of the active ingredient and electrolytes.


Q: Is Movicol similar to products like Lactulose?

A: Both Macrogol and Lactulose are classified as osmotic laxatives, which is a type of medicine that functions by drawing water into the bowel to soften the stool. Clinical evidence frequently uses Lactulose as a comparator when evaluating the effectiveness and safety of Macrogol.


Q: Can Movicol be taken on an empty stomach?

A: Official administration instructions state that the medicine can be taken at any time of the day. The absorption and effectiveness of Macrogol are generally independent of whether it is consumed with or without a meal.


Q: What should I do if I forget a dose of Movicol?

A: According to official patient information, if a dose is forgotten, the general guidance advises that the forgotten dose may be taken once remembered. Patients should then continue with the usual dosing schedule for the remainder of the day.


Q: Why does Movicol come as a sachet you mix with water?

A: The powder is packaged in sachets primarily to ensure the accurate, pre-measured dosage of the active Macrogol 3350. Furthermore, the product must be mixed with the stated volume of water for the necessary osmotic effect to occur in the gastrointestinal tract.


Q: Is Movicol known to cause dehydration?

A: The product is designed with electrolytes to support the maintenance of the body's fluid balance during treatment. However, official warnings state that taking an excessive amount can lead to excessive diarrhea. If severe or prolonged, excessive diarrhea may potentially lead to dehydration or electrolyte imbalance.


Q: Can I mix Movicol with juice instead of water?

A: The powder must first be fully mixed and dissolved in the required amount of water to ensure the proper dose. After it is dissolved, some regulatory information states that flavourings or agents like squash or juice may be added if needed to improve palatability.


Q: Is Movicol suitable for people with diabetes?

A: Suitability for people with diabetes depends on the specific formulation. Official documents describe some varieties of Movicol as being sucrose (sugar) free. However, they may contain artificial sweeteners, which is important information for individuals managing blood sugar levels.


Q: What kind of research has been done on Movicol’s long-term use?

A: Clinical evidence for the active ingredient, Macrogol, is extensive. The research includes systematic reviews and randomised controlled trials (RCTs) that have examined its effectiveness and safety profile for use over extended periods in adults and children.


Q: Do official documents classify Movicol as habit-forming?

A: Official patient information notes that prolonged use of any laxative is generally considered undesirable and may carry a risk of dependence. Regulatory guidance typically advises restricting treatment to two weeks, stating that longer-term use requires medical supervision.


Q: Is Movicol appropriate for elderly users?

A: Yes, official regulatory documents state that the standard formulation is indicated for use in adults and the elderly for the treatment of constipation. Additionally, official information indicates that no specific dose adjustment is listed as being required for older adults.


Q: Can Movicol interact with blood pressure medications?

A: Official interaction warnings state that because Movicol increases the speed of gut transit, it can cause a transient decrease in the absorption of any other oral medicines taken at the same time. This mechanism could potentially affect the plasma exposure of medications such as blood pressure tablets.


Q: Does Movicol contain sugar or artificial sweeteners?

A: While the product is often sucrose (sugar) free, some flavoured varieties may contain an artificial sweetener like acesulfame potassium. Specific excipient lists are available in the official product information for each formulation.


Q: Are there any official warnings about using Movicol with other over-the-counter drugs?

A: The official warning regarding the potential for transiently reduced absorption applies to all co-administered oral medicines. This includes both prescription drugs and other over-the-counter products that are taken by mouth. Official guidance includes a constraint mandating a two-hour separation window to mitigate this risk.


Q: What is the difference between Movicol Plain and Movicol Chocolate/Lemon-Lime?

A: The core of the product remains the same, containing Macrogol 3350 and electrolytes. The difference lies in the excipients, specifically the inclusion of flavouring agents and sometimes different sweeteners or minor components to achieve the desired taste.


Q: Can Movicol be used in patients with restricted fluid intake?

A: Official administration instructions require that each sachet must be dissolved in a specific volume of water (typically 125 ml). Due to the required mixing volume, official information indicates the product is contraindicated for use in patients with severely restricted fluid intake.


Q: Are there known interactions between Movicol and oral contraceptives?

A: Macrogol does not directly interfere with hormonal contraception at the systemic level. However, official guidance notes that if taking Macrogol leads to severe vomiting or prolonged diarrhea, the absorption and effectiveness of the oral contraceptive pill may be reduced.


Q: Why is it important to continue drinking fluids while taking Movicol?

A: Official patient information includes a recommendation that individuals maintain adequate fluid intake while taking the medicine. Although the mixture itself contains water, this fluid is primarily used by the medicine to create the osmotic effect and does not replace the body's normal daily hydration requirements.


Q: Does taking Movicol affect nutrient absorption in the body?

A: Official regulatory documents focus on the transient reduction in the plasma exposure of co-administered oral medicinal products due to increased transit time. Regulatory documents do not contain specific statements regarding the medicine's effect on the absorption of nutrients.


Q: Does Movicol affect how other medicines are absorbed?

A: The physical action of the medicine increases the speed at which contents move through the gastrointestinal tract. Regulatory documents state that this increased transit rate can cause a transient decrease in the plasma exposure of other oral medicinal products. For this reason, official guidance mandates separating the dose of Movicol from other oral medicines by at least one hour before and one hour after.


Q: Is Movicol safe to use during pregnancy?

A: Due to the negligible systemic absorption of the active ingredient, official guidance states that use during pregnancy is generally considered acceptable. Regulatory information indicates that use is reserved for when it is deemed essential and should occur under the direction of a healthcare professional.


Q: Can Movicol be used for long periods?

A: For the treatment of chronic constipation, the standard treatment course is typically restricted to two weeks. However, research suggests that Macrogol is well-tolerated and suitable for use over extended periods. Regulatory documents state that any long-term maintenance use is recommended to be supervised by a healthcare professional.


Q: How is Movicol different from high-fiber supplements?

A: Movicol is classified as an osmotic laxative which acts by chemically drawing and retaining water in the colon to soften and increase stool volume. High-fiber supplements, such as bulk-forming laxatives, work differently by providing undigested mass to mechanically increase stool bulk. Both methods aim to facilitate comfortable bowel movements.


Q: Can taking Movicol interfere with iron supplements?

A: Official warnings about reduced absorption apply to all oral medicines and are not specific to iron supplements. Because iron supplements are taken orally, they fall under the general interaction constraint that may cause a transient reduction in absorption due to accelerated gut transit. A two-hour separation window is advised for all co-administered oral products.

How should Movicol (Macrogol) be stored and disposed of?

How to Store and Dispose of Movicol (Macrogol)

The official storage conditions for Movicol powder for oral solution depend on whether the product is mixed or unmixed. The unopened sachets of powder must be stored below 25°C and do not require special conditions. Conversely, once the powder is dissolved, the reconstituted solution must be stored covered and refrigerated between 2 C and 8 C.

Stability and Disposal

The reconstituted solution typically has an in-use stability limit and must be discarded within 6 hours if not used, or within 24 hours if specified on the label. All forms of the medicine must be kept out of the sight and reach of children.

Medicines should not be disposed of using wastewater or household trash. Any unused product or waste material must be handled in accordance with local requirements, and patients should consult a pharmacist for proper disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Movicol (Macrogol) found in:

A-Z Index: